Summary
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Official Title
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Keywords
Leukemia, B-cell acute lymphoblastic leukemia (ALL), pediatric, multi-agent chemotherapy, JAK inhibitor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoid Leukemia, Leucovorin, Cytarabine, Dexamethasone, Prednisone, Cyclophosphamide, Doxorubicin, Methotrexate, Vincristine, Asparaginase, Mercaptopurine, Pegaspargase, Thioguanine, Levoleucovorin, Ruxolitinib, Asparaginase Erwinia Chrysanthemi, Leucovorin Calcium, Vincristine Sulfate